
Orakl Oncology is a pioneering precision oncology company founded in 2023 as a spin-off from the Gustave Roussy Institute, focused on accelerating oncology drug development through a first-in-class AI-powered techbio platform. The platform integrates real-world patient data with advanced biology to create individualized patient tumor avatars that simulate drug responses, improving clinical trial success rates and patient recruitment. Orakl markets two AI-powered commercial products, O-Predict and O-Validate, which forecast patient responses and provide biological evidence for target validation, respectively. The company targets colorectal and pancreatic cancers, addressing major unmet medical needs, and aims to transform drug development by enabling better decision-making and strategic partnerships with pharmaceutical companies. Orakl has raised nearly €15 million in funding and is building a dedicated business team to support its growth and market entry.

Orakl Oncology is a pioneering precision oncology company founded in 2023 as a spin-off from the Gustave Roussy Institute, focused on accelerating oncology drug development through a first-in-class AI-powered techbio platform. The platform integrates real-world patient data with advanced biology to create individualized patient tumor avatars that simulate drug responses, improving clinical trial success rates and patient recruitment. Orakl markets two AI-powered commercial products, O-Predict and O-Validate, which forecast patient responses and provide biological evidence for target validation, respectively. The company targets colorectal and pancreatic cancers, addressing major unmet medical needs, and aims to transform drug development by enabling better decision-making and strategic partnerships with pharmaceutical companies. Orakl has raised nearly €15 million in funding and is building a dedicated business team to support its growth and market entry.
Founded: 2023 (spin‑out from Gustave Roussy)
Headquarters: Villejuif / Paris region, France
Focus: AI-powered precision oncology using patient-derived tumor avatars (organoids) and multimodal data
Products: O-Predict and O-Validate (AI commercial products)
Known funding: ≈ €14–15M across 2023–2024 (seed / pre-seed rounds)
Preclinical and clinical de-risking for oncology drug discovery and development, with initial tumor-type focus on colorectal and pancreatic cancers.
2023
Biotechnology Research
€3,000,000
Reported pre-seed/seed round
€11,000,000
Seed round with participation from multiple investors
“Singular; Bpifrance; Speedinvest; Verve Ventures; HCVC; SistaFund; Amazon Web Services”
| Company |
|---|
Responsibilities
Qualifications
HR Call (15 minutes call) – An initial discussion to better understand your background, experiences, and motivations.
Technical Interview (60 minutes call) – A deep dive into your technical skills and expertise relevant to the role including a business case
Founder Interview: As final step of our recruitment process, you will meet the COO of Orakl Oncology in person at our office. This meeting is an opportunity for the founder to assess cultural fit and ensure alignment with our company values.